Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines – a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limitsSusan P. Felter, Joel P. Bercu, David J. Ponting et al.|Regulatory Toxicology and Pharmacology|2025Cited by 5
Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity dataRobert A. Jolly, Raechel Puglisi, Gregory R. Ott et al.|Regulatory Toxicology and Pharmacology|2026Cited by 3